FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200901059> ?p ?o ?g. }

• W3200901059 startingPage "237" @default.
• W3200901059 abstract "Background: The outcomes of relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) are very dismal with no standard of therapy. Relapsed or refractory B-NHL are heterogeneous group of lymphoproliferative malignancies with histological, cytogenetic and molecular differences, but all of them have a B-cell receptor. CD79b is a B-cell receptor component and the antibody-drug conjugate polatuzumab vedotin is an anti-CD79b antibody linked to antimitotic agent - monomethyl auristatin E. Polatuzumab vedotin in combination with bendamustine and rituximab (Pola-BR) demonstrated efficacy in patients with r/r B-NHL. Aims: To evaluate the safety and effectiveness of Pola-BR in patients with r/r B-NHL in real clinical practice. Methods: This is interim analysisof single-center prospective study evaluates efficacy and safety of Pola-BR for treatment patients with aggressive r/r B-NHL. All patients received bendamustine 90 mg/m2 on days 1 and 2, rituximab 375 mg/m2 on day 1 and polatuzumab vedotin 1,8 mg/kg on day 1 of each 21-day cycle. The PET-CT scan was performed before treatment initiation and after 2, 4, 6 cycles of Pola-BR. The responses were evaluated using Lugano 2014 criteria. Toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v 4.03. Results: Total of 26 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (n=18), primary mediastinal B-cell lymphoma (PMBCL) (n=7) and gray zone lymphoma (GZL) (n=1) were included. All diagnoses were histologically confirmed. Median age was 43 years (range 20-68). Most of the patients 73% (n=19) had primary chemoresistant disease. The median number of prior therapy lines was 3 (range 2-10). Five patients underwent autologous stem cell transplantation and four patients received anti-CD19 CAR-T cell therapy. At the start of Pola-BR treatment stage III-IV disease had 73% (n=19) patients and 27% (n=7) of patients had bulky disease. Median number of Pola-BR cycles was 4 (range 2-6). Nine patients (35%) completed 6 cycles of Pola-BR. Eight patients (31%) interruptedPola-BR treatment due to disease progression. The overall response rate (ORR) in the group was 61% (n=16) with 46% (n=12) of complete responses (CR) and 15% (n=4) of partial responses (PR). Two patients (8%) had stabilization of the disease as best response. The ORR in patients with DLBCL was 57% (CR 44%), in patients with PMBCL ORR was 57% (CR 43%) and one patient with GZL achieved CR. The ORR in patients with bulky disease was 14% (CR 14%) and ORR 79% (CR 58%) in patients without bulky disease. In patients with relapsed disease ORR was 86% (CR 57%) and in patients with primary chemoresistant disease ORR was 53% (CR 42%). Two patients (50%) with primary CAR-T cell therapy achieved CR. With a median follow up time 6,8 (range 2-12) month overall survival and progression free survival were 71% and 57%, respectively. During Pola-BR treatment grade 3-4 anemia, neutropenia, and thrombocytopenia developed in 19% (n=5), 42% (n=11) and 12% (n=3) patients, respectively. Other adverse events included febrile neutropenia 8% (n=2) and maculopapular rash 8% (n=2). None of the patients had peripheral neuropathy. Two patients with PR died due to Covid-19 infection. Summary/Conclusion: Our real-life data confirms that Pola-BR has an acceptable toxicity profile and it is promising method of immunochemotherapy for patients with r/r B-NHL." @default.
• W3200901059 created "2021-09-27" @default.
• W3200901059 creator A5002109641 @default.
• W3200901059 creator A5026445739 @default.
• W3200901059 creator A5027516224 @default.
• W3200901059 creator A5039979807 @default.
• W3200901059 creator A5051709274 @default.
• W3200901059 creator A5051938700 @default.
• W3200901059 creator A5070314481 @default.
• W3200901059 creator A5079069319 @default.
• W3200901059 creator A5081684163 @default.
• W3200901059 creator A5086319887 @default.
• W3200901059 creator A5089717381 @default.
• W3200901059 date "2021-01-01" @default.
• W3200901059 modified "2023-09-26" @default.
• W3200901059 title "Polatuzumab vedotin in combination with bendamustine and rituximab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: Interim analysis" @default.
• W3200901059 hasPublicationYear "2021" @default.
• W3200901059 type Work @default.
• W3200901059 sameAs 3200901059 @default.
• W3200901059 citedByCount "2" @default.
• W3200901059 countsByYear W32009010592021 @default.
• W3200901059 crossrefType "journal-article" @default.
• W3200901059 hasAuthorship W3200901059A5002109641 @default.
• W3200901059 hasAuthorship W3200901059A5026445739 @default.
• W3200901059 hasAuthorship W3200901059A5027516224 @default.
• W3200901059 hasAuthorship W3200901059A5039979807 @default.
• W3200901059 hasAuthorship W3200901059A5051709274 @default.
• W3200901059 hasAuthorship W3200901059A5051938700 @default.
• W3200901059 hasAuthorship W3200901059A5070314481 @default.
• W3200901059 hasAuthorship W3200901059A5079069319 @default.
• W3200901059 hasAuthorship W3200901059A5081684163 @default.
• W3200901059 hasAuthorship W3200901059A5086319887 @default.
• W3200901059 hasAuthorship W3200901059A5089717381 @default.
• W3200901059 hasBestOaLocation W32009010591 @default.
• W3200901059 hasConcept C121332964 @default.
• W3200901059 hasConcept C126322002 @default.
• W3200901059 hasConcept C142424586 @default.
• W3200901059 hasConcept C143998085 @default.
• W3200901059 hasConcept C159654299 @default.
• W3200901059 hasConcept C197934379 @default.
• W3200901059 hasConcept C203014093 @default.
• W3200901059 hasConcept C2777325958 @default.
• W3200901059 hasConcept C2777793932 @default.
• W3200901059 hasConcept C2778375690 @default.
• W3200901059 hasConcept C2778559949 @default.
• W3200901059 hasConcept C2779338263 @default.
• W3200901059 hasConcept C2780653079 @default.
• W3200901059 hasConcept C2781442060 @default.
• W3200901059 hasConcept C542903549 @default.
• W3200901059 hasConcept C71924100 @default.
• W3200901059 hasConcept C87355193 @default.
• W3200901059 hasConcept C90924648 @default.
• W3200901059 hasConceptScore W3200901059C121332964 @default.
• W3200901059 hasConceptScore W3200901059C126322002 @default.
• W3200901059 hasConceptScore W3200901059C142424586 @default.
• W3200901059 hasConceptScore W3200901059C143998085 @default.
• W3200901059 hasConceptScore W3200901059C159654299 @default.
• W3200901059 hasConceptScore W3200901059C197934379 @default.
• W3200901059 hasConceptScore W3200901059C203014093 @default.
• W3200901059 hasConceptScore W3200901059C2777325958 @default.
• W3200901059 hasConceptScore W3200901059C2777793932 @default.
• W3200901059 hasConceptScore W3200901059C2778375690 @default.
• W3200901059 hasConceptScore W3200901059C2778559949 @default.
• W3200901059 hasConceptScore W3200901059C2779338263 @default.
• W3200901059 hasConceptScore W3200901059C2780653079 @default.
• W3200901059 hasConceptScore W3200901059C2781442060 @default.
• W3200901059 hasConceptScore W3200901059C542903549 @default.
• W3200901059 hasConceptScore W3200901059C71924100 @default.
• W3200901059 hasConceptScore W3200901059C87355193 @default.
• W3200901059 hasConceptScore W3200901059C90924648 @default.
• W3200901059 hasLocation W32009010591 @default.
• W3200901059 hasLocation W32009010592 @default.
• W3200901059 hasLocation W32009010593 @default.
• W3200901059 hasOpenAccess W3200901059 @default.
• W3200901059 hasPrimaryLocation W32009010591 @default.
• W3200901059 hasRelatedWork W2147436770 @default.
• W3200901059 hasRelatedWork W2157105776 @default.
• W3200901059 hasRelatedWork W2346665543 @default.
• W3200901059 hasRelatedWork W2467528896 @default.
• W3200901059 hasRelatedWork W2550264021 @default.
• W3200901059 hasRelatedWork W2555972665 @default.
• W3200901059 hasRelatedWork W2568706726 @default.
• W3200901059 hasRelatedWork W2586530523 @default.
• W3200901059 hasRelatedWork W2594302707 @default.
• W3200901059 hasRelatedWork W2908833725 @default.
• W3200901059 hasRelatedWork W2999153640 @default.
• W3200901059 hasRelatedWork W3030292181 @default.
• W3200901059 hasRelatedWork W3040245446 @default.
• W3200901059 hasRelatedWork W3117647026 @default.
• W3200901059 hasRelatedWork W3145437064 @default.
• W3200901059 hasRelatedWork W3158275756 @default.
• W3200901059 hasRelatedWork W3198517656 @default.
• W3200901059 hasRelatedWork W3199425437 @default.
• W3200901059 hasRelatedWork W3210051517 @default.
• W3200901059 hasRelatedWork W767219806 @default.
• W3200901059 hasVolume "5" @default.
• W3200901059 isParatext "false" @default.
• W3200901059 isRetracted "false" @default.
• W3200901059 magId "3200901059" @default.

• next